Manufacturing & Process Development
Fast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilities
By: Joanna Wirkus Despite exponential progress in the field of biology, inherited and preventable diseases continue to burden billions of people worldwide. Bridging the gap between laboratory discoveries and transformative clinical therapies remains a significant challenge, , and an urgent opportunity. High-quality biospecimens are foundational to this effort, enabling the advancement of cell and gene…
For More InformationCGT Sourcing Guide 2025: How to Build a Resilient Supply Chain Amid Tariff Pressures
By CGT Global The latest round of U.S. tariffs didn’t just shake up the headlines—it shook the very foundations of global pharma supply chains. And while most of the buzz has focused on traditional drugmakers, let’s be clear: cell and gene therapy manufacturers aren’t sitting this one out. For companies working with high-value, time-sensitive materials…
For More InformationHow to Improve Humanized Mouse Engraftment: CD34+ Cell Sourcing & Viability Tips
By: Joanna Wirkus Simple Steps to Significantly Improve Humanized Mice Engraftment Success Previously in “Overcoming Challenges with Animal Models in Research”, we covered why animal models with human immune systems have significantly improved the translation of preclinical findings into life-saving treatments. Successfully creating these advanced models for testing new therapies relies on high hematopoietic stem…
For More InformationCord Blood CD34+ Cells: High Viability for Humanized Mouse Models
By: Joanna Wirkus The Rise of Cord Blood CD34+ Cells in Humanized Mouse Models and Cell Therapy Innovation Scientists in the late 1980’s discovered that umbilical cord blood derived stem cells had high proliferative potential and tolerated cryopreservation and thawing (Broxmeyer, 1989). Building on this research, the first report of cord blood derived CD34+ human…
For More InformationBuffy Coat vs. Leukapheresis: Choosing the Right Cell Source for Your Research
By: Joanna Wirkus Choosing Between Buffy Coat and Leukapheresis: A Guide for Scientists When your research hinges on high-quality, primary immune cells, starting with the right biological material can make or break your experiment. One of the most common questions we hear from scientists is: Should I use buffy coat- or leukapheresis-derived cells? The answer…
For More InformationCryopreservation in Cell and Gene Therapy: Ensuring High-Viability Cells for Research & Manufacturing
By Joanna Wirkus The Role of Cryopreservation in Cell and Gene Therapy Cryopreservation is a cornerstone of cell and gene therapy, enabling the long-term storage and viability of vital cell types such as CD34+ hematopoietic stem cells, mesenchymal stem cells (MSCs), natural killer (NK) cells, and T cells used in CAR-T therapies. Interestingly, nature has…
For More InformationCellsExpress: Affordable, Bulk Isolated Bone Marrow-Derived Stem Cells That Accelerate Your Cell and Gene Therapy Research
By Joanna Wirkus Bulk Bone Marrow Stem Cells for Research | CGT Global The race to develop life-saving cell and gene therapies is intensifying. Amid shifting political pressures, uncertain funding landscapes, and rising inflation, scientists are being asked to do more with less. Time, money, and labor must be optimized at every step—and that starts…
For More Information